Request Demo
Last update 25 Apr 2025
SGN-CD19B
Last update 25 Apr 2025
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms SGN CD19B |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC18H27N3O6 |
InChIKeyGSWKJIWKGSPISH-LRDDRELGSA-N |
CAS Registry- |
View All Structures (2)
Boost your research with our ADC technology data.
login
or
Sequence Code 61062H
Sequence Code 61128L
Related
1
Clinical Trials associated with SGN-CD19BNCT02702141
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
100 Clinical Results associated with SGN-CD19B
Login to view more data
100 Translational Medicine associated with SGN-CD19B
Login to view more data
100 Patents (Medical) associated with SGN-CD19B
Login to view more data
1
Literatures (Medical) associated with SGN-CD19B02 Nov 2017Blood
Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies
Article
Author: Ryan, Maureen C. ; Gordon, Kristine A. ; Kostner, Heather ; Palanca-Wessels, Maria Corinna ; Van Epps, Heather A. ; Schimpf, Brian ; Meyer, Brad ; Yu, Changpu ; Benjamin, Dennis
Key Points:
SGN-CD19B is broadly active in vitro against malignant B-cell lines, including double-hit and triple-hit lymphoma cell lines. SGN-CD19B shows significant antitumor activity in vivo in preclinical models of B-NHL and B-cell–derived acute lymphoblastic leukemia.
100 Deals associated with SGN-CD19B
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 1 | United States | 01 Feb 2016 | |
| Follicular Lymphoma | Phase 1 | United States | 01 Feb 2016 | |
| Refractory Aggressive Non-Hodgkin Lymphoma | Phase 1 | United States | 01 Feb 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free